Novogene Co., Ltd. (688315.SS)
CNY 14.06
(0.21%)
CNY 14.06
(0.21%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 369.4 Million CNY | -2.41% |
| 2022 | 343.02 Million CNY | 1.35% |
| 2021 | 387.78 Million CNY | 136.32% |
| 2020 | 157.92 Million CNY | -26.07% |
| 2019 | 214.48 Million CNY | 10.52% |
| 2018 | 199.66 Million CNY | 41.02% |
| 2017 | 146.89 Million CNY | 87.99% |
| 2016 | 78.15 Million CNY | 62.39% |
| 2015 | 50.26 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 37.99 Million CNY | -51.21% |
| 2024 Q2 | 91 Million CNY | 92.82% |
| 2024 Q3 | 63.88 Million CNY | -37.84% |
| 2023 Q2 | 63.44 Million CNY | 99.02% |
| 2023 Q3 | 64.31 Million CNY | 1.38% |
| 2023 Q4 | 77.03 Million CNY | 19.77% |
| 2023 Q1 | 31.87 Million CNY | -71.31% |
| 2023 FY | - CNY | -2.41% |
| 2022 Q1 | 22.15 Million CNY | -80.35% |
| 2022 Q4 | 111.09 Million CNY | 35.86% |
| 2022 Q3 | 81.77 Million CNY | 76.91% |
| 2022 Q2 | 46.22 Million CNY | 108.61% |
| 2022 FY | - CNY | 1.35% |
| 2021 Q3 | 56.45 Million CNY | 0.98% |
| 2021 FY | - CNY | 136.32% |
| 2021 Q4 | 112.73 Million CNY | 99.71% |
| 2021 Q2 | 55.9 Million CNY | 74.87% |
| 2021 Q1 | 31.96 Million CNY | 103.52% |
| 2020 Q3 | 1.02 Billion CNY | 447.4% |
| 2020 Q2 | -295.73 Million CNY | -232.83% |
| 2020 FY | - CNY | -26.07% |
| 2020 Q1 | 222.63 Million CNY | 127.05% |
| 2020 Q4 | -908.47 Million CNY | -188.43% |
| 2019 Q4 | -823.17 Million CNY | -190.22% |
| 2019 Q3 | 912.4 Million CNY | 608.64% |
| 2019 Q2 | -179.38 Million CNY | -184.59% |
| 2019 FY | - CNY | 10.52% |
| 2019 Q1 | 212.05 Million CNY | 249.97% |
| 2018 Q1 | 29.67 Million CNY | 0.0% |
| 2018 Q4 | 60.59 Million CNY | 0.0% |
| 2018 FY | - CNY | 41.02% |
| 2018 Q3 | 60.59 Million CNY | 104.15% |
| 2018 Q2 | 29.67 Million CNY | 0.0% |
| 2017 FY | - CNY | 87.99% |
| 2016 FY | - CNY | 62.39% |
| 2015 FY | - CNY | 0.0% |